Nowadays, considerable resources are invested into basic science but the question arises of whether it efficiently leads to the development of new therapies and can justify its cost in comparison to clinical, translational research. Following a recession, Brexit, Donald Trump and a snap general election, the government and how it behaves has never been under such scrutiny by the general public. As such, funding the endeavours of an ivory tower scientist becomes less and less of a priority, whilst the need for life saving treatments is only increasing. What is the route of the next big discovery? Will academia, with its track record of sparking world changing discoveries lead to the development of new drugs, therapies and devices, or will clinical, translational research take the crown (and the funding)? Join us on June 13th at the Judge Business school, University of Cambridge, for what promises to be a lively discussion between four different fields each invested in this question.
GUEST SPEAKERS: BEN BLEASDALE, PETER HISCOCKS, TAMZIN BYRNE
UNIVERSITY OF CAMBRIDGE JUDGE BUSINESS SCHOOL (7-9 PM)
Ben Bleasdale is currently a Senior Policy officer at Wellcome Trust. He obtained his PhD in Virology at Imperial College London, before finding himself in the position of Policy Officer at the Academy of Medical Sciences.
Peter Hiscocks is the CEO of Cambridge Judge Business School Executive Education, as well as a lecturer in entrepreneurship and innovation management. He was also the Director of Cambridge Enterprise as well as the first Director of the Cambridge Entrepreneurship Centre. In the past he spent a number of years in the private sector working in product development in large companies before starting his own businesses, a few of which have been very successful and sold. He is also the Chairman of a £20 million seed-fund that helps fund new business start-ups and is on the advisory boards of a large venture capital company.
Tamzin Byrne is the Programme Coordinator of Cambridge Social Ventures. With a background in journalism and science communication, she has written about everything from the God particle to stem cells for universities, government agencies, international research centres and start-ups.